ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2

References

• Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ (Clin Res Ed). 2021;375:n2026.
   PubMedGoogle Scholar
• Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56:84–89.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Tallman MS, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Curr Opin Oncol. 2021;33:658–669.
   PubMed Web of Science ®Google Scholar
• Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196:316–328.
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267–1291.
   PubMed Web of Science ®Google Scholar
• Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-Mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–5667.
   PubMed Web of Science ®Google Scholar
• Tan YT, Lin JF, Li T, et al. LncRNA-Mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41(2):109–120.
   PubMed Web of Science ®Google Scholar
• Feng Y, Hu S, Li L, et al. Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML). Cell Death Amp Dis. 2020;11:1025.
   PubMed Web of Science ®Google Scholar
• Zuo W, Zhou K, Deng M, et al. LINC00963 facilitates acute myeloid leukemia development by modulating miR-608/MMP-15. Aging (Albany NY). 2020;12:18970–18981.
   PubMedGoogle Scholar
• Chen L, Wang W, Cao L, et al. Long non-coding RNA CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia. Mol Cells. 2016;39:330–336.
   PubMed Web of Science ®Google Scholar
• Cai T, Cui X, Zhang K, et al. LncRNA TNK2-AS1 regulated ox-LDL-stimulated HASMC proliferation and migration via modulating VEGFA and FGF1 expression by sponging miR-150-5p. J Cell Mol Med. 2019;23(11):7289–7298.
   PubMed Web of Science ®Google Scholar
• Yao W, Yan Q, Du X, et al. TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319/WDR1. Cancer Sci. 2020;112(2):893–905.
   PubMed Web of Science ®Google Scholar
• Gourvest M, Brousset P, Bousquet M. Long noncoding RNAs in acute myeloid leukemia: functional characterization and clinical relevance. Cancers (Basel). 2019;11(11):11.
   Web of Science ®Google Scholar
• Guo L, Ma H, Kong Y, et al. Long non-coding RNA TNK2 AS1/microRNA-125a-5p axis promotes tumor growth and modulated phosphatidylinositol 3 kinase/akt pathway. J Gastroenterol Hepatol. 2022;37:124–133.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen S, Song X, et al. Elk1/lncrna-Snhg7/mir-2682-5p feedback loop enhances bladder cancer cell growth. Life Sci. 2020;262:118386.
   PubMed Web of Science ®Google Scholar
• Ma SP, Xi HR, Gao XX, et al. Long noncoding RNA HBBP1 enhances γ-globin expression through the ETS transcription factor ELK1. Biochem Biophys Res Commun. 2021;552:157–163.
   PubMed Web of Science ®Google Scholar
• Ma G, Dai W, Zhang J, et al. Elk1‑mediated upregulation of lncRNA LBX2‑AS1 facilitates cell proliferation and invasion via regulating miR‑491‑5p/s100a11 axis in colorectal cancer. Int J Mol Med. 2021;48. DOI:10.3892/ijmm.2021.4971
   Web of Science ®Google Scholar
• Gao S, Zhou B, Li H, et al. Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15. Exp Hematol. 2018;67:32–40.e3.
   PubMed Web of Science ®Google Scholar
• Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.
   PubMed Web of Science ®Google Scholar
• Qi W, Zhao K, Gu J, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 2017;13:381–388.
   PubMed Web of Science ®Google Scholar
• Zang X, Gu J, Zhang J, et al. Exosome-Transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Amp Dis. 2020;11:215.
   PubMed Web of Science ®Google Scholar
• Xu DF, Tao XH, Yu Y, et al. LncRNA FOXC2-AS1 stimulates proliferation of melanoma via silencing p15 by recruiting EZH2. Eur Rev Med Pharmacol Sci. 2020;24(17):8940–8946.
   PubMed Web of Science ®Google Scholar
• Liu J, Li Z, Yu G, et al. LINC01232 promotes gastric cancer proliferation through interacting with EZH2 to inhibit the transcription of KLF2. J Microbiol Biotechnol. 2021;31:1358–1365.
   PubMed Web of Science ®Google Scholar
• Guo Q, Wu Y, Guo X, et al. The RNA-binding protein CELF2 inhibits ovarian cancer progression by stabilizing FAM198B. Mol Ther Nucl Acids. 2021;23:169–184.
   Google Scholar
• Wang L, Liu Z, Liu L, et al. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: a pan-cancer analysis. J Cell Mol Med. 2021;25(15):7559–7574.
   PubMed Web of Science ®Google Scholar
• New J, Subramaniam D, Ramalingam S, et al. Pleotropic role of RNA binding protein CELF2 in autophagy induction. Mol Carcinog. 2019;58(8):1400–1409. DOI:10.1002/mc.23023
   PubMed Web of Science ®Google Scholar
• Shi M, Yang R, Lin J, et al. LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN/PI3K/AKT axis through suppressing CELF2 protein. J Biosci. 2021;46. DOI:10.1007/s12038-020-00127-1
   Web of Science ®Google Scholar
• Xie SC, Zhang JQ, Jiang XL, et al. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Amp Dis. 2020;11(8):676.
   PubMed Web of Science ®Google Scholar
• Wu JZ, Jiang N, Lin JM, et al. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2020;24(6):2977–2985.
   PubMed Web of Science ®Google Scholar
• Nepstad I, Hatfield KJ, Grønningsæter IS, et al. The PI3K-Akt-mTOR signaling pathway in human Acute Myeloid Leukemia (AML) cells. Int J Mol Sci. 2020;21(8):21.
   Web of Science ®Google Scholar
• Nepstad I, Hatfield KJ, Grønningsæter IS, et al. The PI3K-Akt-mTOR signaling pathway in human Acute Myeloid Leukemia (AML) cells. Int J Mol Sci. 2020;21(8):21.
   Web of Science ®Google Scholar